CN113208013A - 一种化香虫茶及其生产方法与应用 - Google Patents
一种化香虫茶及其生产方法与应用 Download PDFInfo
- Publication number
- CN113208013A CN113208013A CN202110503612.2A CN202110503612A CN113208013A CN 113208013 A CN113208013 A CN 113208013A CN 202110503612 A CN202110503612 A CN 202110503612A CN 113208013 A CN113208013 A CN 113208013A
- Authority
- CN
- China
- Prior art keywords
- tea
- champignon
- insect
- production method
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000238631 Hexapoda Species 0.000 title claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 241001122767 Theaceae Species 0.000 title 1
- 244000269722 Thea sinensis Species 0.000 claims abstract description 182
- 244000251953 Agaricus brunnescens Species 0.000 claims abstract description 109
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 109
- 241000254109 Tenebrio molitor Species 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 241001265525 Edgeworthia chrysantha Species 0.000 claims description 19
- 102000040945 Transcription factor Human genes 0.000 claims description 12
- 108091023040 Transcription factor Proteins 0.000 claims description 12
- 108091000080 Phosphotransferase Proteins 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 102000020233 phosphotransferase Human genes 0.000 claims description 11
- 239000004576 sand Substances 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 22
- 239000001301 oxygen Substances 0.000 abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 abstract description 13
- 229910052742 iron Inorganic materials 0.000 abstract description 11
- 230000009467 reduction Effects 0.000 abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
- 230000002000 scavenging effect Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 235000013616 tea Nutrition 0.000 description 163
- 239000000243 solution Substances 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000284 extract Substances 0.000 description 33
- 239000000523 sample Substances 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- 239000004480 active ingredient Substances 0.000 description 21
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 20
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 20
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 20
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 20
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 20
- 235000005493 rutin Nutrition 0.000 description 20
- 229960004555 rutoside Drugs 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- -1 hydroxyl radicals Chemical class 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 15
- 230000002292 Radical scavenging effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000003032 molecular docking Methods 0.000 description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229930003944 flavone Natural products 0.000 description 7
- 150000002212 flavone derivatives Chemical class 0.000 description 7
- 235000011949 flavones Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 7
- 235000006468 Thea sinensis Nutrition 0.000 description 6
- 235000020279 black tea Nutrition 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- 238000010201 enrichment analysis Methods 0.000 description 6
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 4
- 241000305549 Platycarya strobilacea Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- QSQLTHHMFHEFIY-UHFFFAOYSA-N methyl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC QSQLTHHMFHEFIY-UHFFFAOYSA-N 0.000 description 4
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 4
- JGHZJRVDZXSNKQ-UHFFFAOYSA-N methyl octanoate Chemical compound CCCCCCCC(=O)OC JGHZJRVDZXSNKQ-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000002299 Symphytum officinale Species 0.000 description 3
- 235000005865 Symphytum officinale Nutrition 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CVZZNRXMDCOHBG-QMMMGPOBSA-N 2-Chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1Cl CVZZNRXMDCOHBG-QMMMGPOBSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- DFNOHNMHWQVJHX-UHFFFAOYSA-N Ginsenoyne H Chemical compound CC(=O)OC(CC)C#CC#CCC1OC1CCCCCC=C DFNOHNMHWQVJHX-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- VHUJBYYFFWDLNM-UHFFFAOYSA-N Methyl Hexacosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC VHUJBYYFFWDLNM-UHFFFAOYSA-N 0.000 description 2
- 239000005641 Methyl octanoate Substances 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 241001477931 Mythimna unipuncta Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 102000007641 Trefoil Factors Human genes 0.000 description 2
- 235000015724 Trifolium pratense Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- QGBRLVONZXHAKJ-UHFFFAOYSA-N methyl arachidate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC QGBRLVONZXHAKJ-UHFFFAOYSA-N 0.000 description 2
- YRHYCMZPEVDGFQ-UHFFFAOYSA-N methyl decanoate Chemical compound CCCCCCCCCC(=O)OC YRHYCMZPEVDGFQ-UHFFFAOYSA-N 0.000 description 2
- IJXHLVMUNBOGRR-UHFFFAOYSA-N methyl nonanoate Chemical compound CCCCCCCCC(=O)OC IJXHLVMUNBOGRR-UHFFFAOYSA-N 0.000 description 2
- XUDJZDNUVZHSKZ-UHFFFAOYSA-N methyl tetracosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC XUDJZDNUVZHSKZ-UHFFFAOYSA-N 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004879 molecular function Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RUZIUYOSRDWYQF-HNNXBMFYSA-N (S)-glaucine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC)=C1 RUZIUYOSRDWYQF-HNNXBMFYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BLFGQHDZMHMURV-UHFFFAOYSA-N 4-oxo-2-phenylchromene-3-carboxylic acid Chemical compound O1C2=CC=CC=C2C(=O)C(C(=O)O)=C1C1=CC=CC=C1 BLFGQHDZMHMURV-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- DZUXGQBLFALXCR-BMPPNWMBSA-N 7-[(1R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)\C=C\C1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-BMPPNWMBSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100033093 Calcium/calmodulin-dependent protein kinase type II subunit alpha Human genes 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 235000003244 Canarium schweinfurthii Nutrition 0.000 description 1
- 244000139184 Canarium schweinfurthii Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000254171 Curculionidae Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 description 1
- KYKWIMFWAYVDJI-UHFFFAOYSA-N Furomammea G Chemical compound C1=2CC(C(C)(C)O)OC=2C(C(=O)CC(C)C)=C(O)C2=C1OC(=O)C=C2CCC KYKWIMFWAYVDJI-UHFFFAOYSA-N 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- DABPOQZSGVNAAS-UHFFFAOYSA-N Glaucocalactone Natural products O=CC12C3C(C4)OC(=O)C2C(C)(C)CCC1OC(=O)C13CC4C(=C)C1OC(=O)C DABPOQZSGVNAAS-UHFFFAOYSA-N 0.000 description 1
- 101000944249 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit alpha Proteins 0.000 description 1
- 101000974816 Homo sapiens Calcium/calmodulin-dependent protein kinase type IV Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000809045 Homo sapiens Nucleolar transcription factor 1 Proteins 0.000 description 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 description 1
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 101000671637 Homo sapiens Upstream stimulatory factor 1 Proteins 0.000 description 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
- 101000759547 Homo sapiens Zinc finger and BTB domain-containing protein 7A Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000005087 Malus prunifolia Nutrition 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 239000005640 Methyl decanoate Substances 0.000 description 1
- VUVUIDMZOWHIIJ-UHFFFAOYSA-N Methyl-n-nonadecyl-keton Natural products CCCCCCCCCCCCCCCCCCCC(C)=O VUVUIDMZOWHIIJ-UHFFFAOYSA-N 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- ZTSDUAUVRSWDNM-UHFFFAOYSA-N NC(=N)NC(=N)NCCC1=CC(Cl)=C(I)C=C1 Chemical compound NC(=N)NC(=N)NCCC1=CC(Cl)=C(I)C=C1 ZTSDUAUVRSWDNM-UHFFFAOYSA-N 0.000 description 1
- 241001600484 Niphona Species 0.000 description 1
- 241001435156 Nodaria Species 0.000 description 1
- 102100038485 Nucleolar transcription factor 1 Human genes 0.000 description 1
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 1
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- 241000543509 Tridentiger Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 241001436151 Turpinia arguta Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 102100040105 Upstream stimulatory factor 1 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100023264 Zinc finger and BTB domain-containing protein 7A Human genes 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- CQAYJDMWUGRKOJ-UHFFFAOYSA-N acetyloxy-oxido-oxophosphanium Chemical compound CC(=O)O[P+]([O-])=O CQAYJDMWUGRKOJ-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- AZGSCHIQUAKTNP-UHFFFAOYSA-N brosimacutin D Natural products O1C2=C3CC(O)C(C)(C)OC3=CC=C2C(=O)CC1C1=CC=C(O)C=C1 AZGSCHIQUAKTNP-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical class C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001599 direct drying Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940113086 glaucine Drugs 0.000 description 1
- 229930004041 glaucine Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 150000002435 hydroquinone lipids Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- AFTLVCKDKPSOGG-UHFFFAOYSA-N o-methylhydroxylamine;pyridine;hydrochloride Chemical compound Cl.CON.C1=CC=NC=C1 AFTLVCKDKPSOGG-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/90—Feeding-stuffs specially adapted for particular animals for insects, e.g. bees or silkworms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Husbandry (AREA)
- Insects & Arthropods (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biodiversity & Conservation Biology (AREA)
Abstract
本发明公开了一种化香虫茶及其生产方法与应用,属于食品技术领域。所述的化香虫茶的生产方法为利用黄粉虫幼虫处理化香树叶得到化香虫茶。按照本发明所述方法生产的化香虫茶产量比较可观,与传统方法生产的虫茶相比,周期更短;而且黄粉虫可在室内养殖,可将其圈定在饲养盒内进行规模养殖,易于统一管理。按照本发明所述方法生产的化香虫茶具有较好的氧自由基、羟基自由基、DPPH自由基的清除能力和铁还原能力。
Description
技术领域
本发明涉及食品技术领域,特别涉及一种化香虫茶及其生产方法与应用。
背景技术
虫茶,又名“虫酿茶”、“虫粪茶”或“虫屎茶”。传统意义上的“虫茶”中的虫并不是它的原料,而是它的生产者,其茶即是生产产物;换言之,在虫茶的制作过程中,将昆虫比喻为生产的机器,特定植物将会通过昆虫的消化道进行加工,经一系列的生化活动(消化酶或肠道微生物的发酵),特定植物转化为可供人类易于吸收或具有保健功能的发酵品。文礼章认为虫茶的功能主要取决于所采用的不同植物,与昆虫本身可能没有直接的关系,特定植物的相关成份经过虫体消化道发酵之后被富集于虫茶中。所以,虫茶既不是“被昆虫取食过的茶叶”,也不是“利用昆虫制作的茶饮”,而是源于昆虫取食特定的植物后产出的具有特定功能的粪便。
目前虫茶主要由农村的农户生产为主,一般采用传统的制作方法。三叶虫茶的制作,一般在每年的5至7月份,需采摘新鲜的三叶海棠嫩叶;将其经过高温杀青、晾干、装桶等处理后,并在表面喷撒一些淘米水;放置于阴暗通风的角落或阁楼上,自然发酵十天左右会散发特殊的气味以吸引米缟螟在原料表面产卵;待虫卵孵化成幼虫后便会取食这些原料进而排泄其虫粪,这个过程一般持续1.5至3年,收集到的昆虫排泄物为三叶虫茶。化香虫茶和老鹰茶虫茶的制作流程与三叶虫茶相似,化香虫茶的制作一般在6至7月或11月至12月采摘化香树叶,只要2至3天即可散发原料的清香气味,收集虫茶后续鼓风除杂和暴晒;而老鹰茶虫茶需要11个月以上的制作周期。总之,传统的虫茶制作过程比较费时,且产量较低。
虫茶含有丰富的营养成份,例如粗蛋白、脂肪酸、糖类、黄酮类等。文礼章团队的测定结果表明,三叶虫茶中必需氨基酸、铜、锌、钙、镁等含量显著高于传统茶叶的研究表明,老鹰茶虫茶的蛋白质、总糖含量、脂肪、矿物质等与绿茶的水平相当,其中人体必需的氨基酸有Lys、Val、Ile、Phe、Leu和Trp。
传统虫茶指的是将特定的昆虫在人为控制的情况下喂食某种特定的植物所产生的排泄物。例如,化香虫茶的传统生产方式是采用野外化香夜蛾(Hydrillodes morosa)、雪疽夜蛾(Nodaria niphona)、弓须亥夜蛾(Hydrillodes repugnalis)等鳞翅目昆虫取食化香树叶(Platycarya strobilacea)进行生产化香虫茶。这些昆虫的食性相对单一,并且野生昆虫可能沾染一些霉菌或有毒物质等。目前,传统虫茶主要以农村家庭生产为主,少数企业有半规模性生产,采用自然的生产模式,存在产量低下、卫生条件差、生产工艺落后等问题。虫茶是中国茶类中的特色茶饮,其具有抗氧化性、抗炎、降血糖、降脂、降压等生物功能。国内学者对虫茶的相关研究仅限于部分类型虫茶的氨基酸、脂肪酸、矿物质或一些化学成份的简单分析,缺乏更具体的成药组分、药理机制等深入的研究,也没有引起中医药领域对虫茶的重视。而且目前国外尚未见有将虫茶或相关昆虫排泄物用于制作饮品、药物的相关报道。
发明内容
本发明的首要目的在于克服现有技术的缺点与不足,提供一种化香虫茶的生产方法。
本发明的另一目的在于提供通过上述生产方法得到的化香虫茶。
本发明的再一目的在于提供上述化香虫茶的应用。
本发明的目的通过以下技术方案来实现:
一种化香虫茶的生产方法,利用黄粉虫幼虫处理化香树叶得到化香虫茶。
具体地,该方法是以化香树叶饲养黄粉虫幼虫,将黄粉虫幼虫生产的虫沙烘干即得化香虫茶。
所述的黄粉虫幼虫优选为60~90日龄的黄粉虫幼虫。
所述的化香树叶优选为经烘干后的化香树叶嫩叶;进一步优选为经烘干后的裁剪至长宽为0.5~1.5cm的化香树叶嫩叶;更优选为经烘干后的裁剪至长宽为1cm的化香树叶嫩叶。
所述的黄粉虫幼虫密度优选为0.088~0.269g/cm2;更优选为0.179g/cm2。
所述的烘干为恒温烘干;优选为50~70℃恒温烘干2~4h;更优选为60℃恒温烘干3h。
所述的烘干前还包括过筛的操作;所述的过筛优选为过30~60目筛;更优选过40目筛。
所述的饲养的条件优选为通风干燥、卫生的环境中;更优选为通风干燥、卫生,每隔6h喷洒雾状无菌水的环境中。
一种化香虫茶,通过上述生产方法制备得到。
上述化香虫茶在制备治疗和/或预防由相关激酶或转录因子作用引起的疾病的药物中的应用。
所述的由相关激酶或转录因子作用引起的疾病包括癌症、炎症、免疫相关疾病、血管、白血病相关疾病、肥胖相关疾病、肌肉相关疾病和骨质相关疾病中的至少一种;更优选为癌症、炎症、病毒感染、高血脂和血管疾病中的至少一种。
本发明相对于现有技术具有如下的优点及效果:
(1)按照本发明所述方法生产的化香虫茶产量比较可观,与传统方法生产的虫茶相比,周期更短;而且黄粉虫可在室内养殖,可将其圈定在饲养盒内进行规模养殖,易于统一管理。
(2)按照本发明所述方法生产的化香虫茶具有较好的氧自由基、羟基自由基、DPPH自由基的清除能力和铁还原能力。
(3)化香虫茶的主要活性成份具有多靶点的作用,其在细胞内主要调控21种中枢蛋白,以进一步影响相关协作蛋白的功能。化香虫茶的主要活性成份在癌症、炎症、病毒感染、高脂肪和血管疾病等方面有一定的防治潜力。
附图说明
图1为化香虫茶(At)、化香树叶(Ah)和市售化香虫茶(Af)对羟基自由基清除率的分析结果图。
图2为芦丁溶液对羟基自由基清除率的分析结果图。
图3为各样品对羟基自由基清除能力的分析结果图。
图4为各样品对DPPH自由基清除率的分析结果图。
图5为芦丁溶液对DPPH自由基清除率的分析结果图。
图6为各样品清除DPPH自由基能力的分析结果图。
图7为各样品还原二价铁的能力分析结果图。
图8为芦丁溶液还原二价铁的能力分析结果图。
图9为各样品的铁还原能力分析结果图。
图10为各样品对氧自由基清除率的分析结果图。
图11为各样品对氧自由基清除能力的分析结果图。
图12为化香树叶(Ah)、市售化香虫茶(Af)和化香虫茶(At)的显著上调成份的韦恩图;其中,化香树叶(Ah)定义为H组、市售化香虫茶(Af)为F组、化香虫茶(At)为T1组;F_H_up为F组比较H组显著上调的化学成份;T1_H_up为T1组比较H组显著上调的化学成份;T1_F_up为T1组比较F组显著上调的化学成份。
图13为化香树叶(Ah)、市售化香虫茶(Af)和化香虫茶(At)的显著下调成份的韦恩图;其中,化香树叶(Ah)定义为H组、市售化香虫茶(Af)为F组、化香虫茶(At)为T1组;F_H_down为F组比较H组显著下调的化学成份;T1_H_down为T1组比较H组显著下调的化学成份;T1_F_down为T1组比较F组显著下调的化学成份。
具体实施方式
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。
实施例1:化香虫茶的制备
将60日龄的黄粉虫于14cm×8cm的饲养盒中,黄粉虫密度分别为0.089、0.179、0.268g/cm2(即每平方厘米饲养盒中分别含有均重为0.089g、0.179g、0.268g的黄粉虫),每组三个平行,将化香树叶嫩叶烘干后裁剪至长宽为1cm大小以铺盖的形式投喂于每个盒子饲喂黄粉虫,每个盒中投加10g左右的黄粉虫,20g左右的黄粉虫,30g左右的黄粉虫,每个盒均投放1g左右的干燥化香树嫩叶。隔6个小时适量喷洒雾状水分,每24小时收集盒子中的虫沙并及时添加原料,饲养周期为7天,收集的虫沙过40目筛后置于60℃恒温烘箱3个小时即得化香虫茶,随后称重,同时观察和记录黄粉虫的取食情况,计算7天内化香虫茶的生产率。化香虫茶每天的其中,M虫砂为收集虫砂的重量(g);M虫为盒子中黄粉虫的重量(g);M植物为单次投喂烘干后的化香树叶的重量(g)。
结果如表1所示。
表1:化香虫茶的生产率
结果表明,在相同的饲养空间下,随着黄粉虫密度的增加,其生产的虫沙也随之增加,但随着密度增大到一定程度,化香虫茶的生产率反而下降,说明黄粉虫的密度会影响其取食,原因可能是在饲养盒底部的黄粉虫不易接触投放的原料(化香树叶)。综上所述,基于14cm×8cm的饲养盒下所生产化香虫茶的每日平均生产率为3.17%。
实施例2:不同化香虫茶的性能测定
1.理化指标
分别测定实施例1制备得到的化香虫茶(At)与化香树叶(Ah)(购于河南南阳市)和市售化香虫茶(Af)(购自广西桂林市龙胜自治县;下同)的干物质含量、水分含量、总灰分含量、水浸出物含量和粗纤维含量;其中,干物质含量依据国家标准(GB/T 8303-2013)测定;水分含量依据国家标准(GB 5009.3-2016)中的直接干燥法测定;总灰分含量依据国家标准(GB5009.4-2016)中第一法测定;水浸出物含量依据国家标准(GB/T 8305-2013)测定;粗纤维含量依据国家标准(GB/T 8310-2013)测定。结果如表2所示。
表2:化香树叶、市售化香虫茶及实施例1的化香虫茶的理化性质
表2的结果表明,黄粉虫生产的化香虫茶(At)与市售化香虫茶(Af)的含水率无显著差异;At、Af比Ah的含水率低,说明市售化香虫茶(Af)和化香虫茶(At)比化香树叶(Ah)更稳定,更利于长期保存。通过比较干物质的含量,这三种样品的干物质重量由大到小依次为At>Af>Ah。这三种样品的总灰分无显著差异,其中At的总灰分最高,总体比国家标准(ISO3720:2011)规定的红茶总灰分上限8%要高一点,说明虫茶(Af和At)的矿物质含量可能比部分红茶多。虫茶(Af和At)与原料(Ah)的水浸出物含量无显著差异,且这三种样品的水浸出物含量比国家标准(ISO 3720:2011)规定的红茶水浸出物下限34%要明显更高。根据国家标准(ISO 3720:2011)建议以16.5%作为红茶的粗纤维最高限量,说明本发明由黄粉虫饲养化香树叶生产的化香虫茶(At)符合红茶粗纤维含量的标准。综上所述,由黄粉虫生产的虫茶(At)与市售虫茶的4项理化指标(水分、干物质、总灰分和水浸出物)无明显差异,虫茶的水浸出物含量比国标规定的红茶表现更优。
2.化香虫茶的抗氧化性研究
(1)化香虫茶水提取液的制备
将一定量晒干的化香树叶放入粉碎机进行粉碎,粉碎后过60目筛以剔除过于细小的粉末,再过40目筛即得到待用的粉末。精密称量化香树叶粉末(Ah)、市售化香虫茶(Af)、实施例1制备得到的化香虫茶(At)各2g,将其分别倒入索氏提取器内,分别按料液比1:20加入蒸馏水,进行沸水浴浸提,每次提取时间为1.5小时,重复三次,每次收集水提液后按料液比补充蒸馏水,将三次已冷却的水提液合并后进行过滤和10000×g 4℃离心20分钟,将离心后的上清液分别定容至200mL,即得到10mg/mL的样品待测液,即分别得到化香树叶水提取液、市售化香虫茶水提取液、实施例1制备得到的化香虫茶水提取液。
(2)化香虫茶中总黄酮含量的检测
芦丁标准母液的制备:精密称量芦丁0.1g,倒入50mL的烧杯中;加入15mL的30%(v/v)乙醇溶液,在微热下条件下使搅拌溶解;反复加入几次30%乙醇溶液,直至芦丁完全溶解在溶液中;再将其定容至100mL即得到1mg/mL的芦丁标准母液,备用。
芦丁标准曲线的绘制:根据1:3的比例,精确吸取芦丁标准母液、30%(v/v)乙醇溶液于烧杯中,搅拌后即得到浓度为0.25mg/mL的芦丁待测液。准确量取芦丁待测液0.00、0.20、0.60、1.20、1.80、2.40、3.00mL于7支具塞试管中,分别用30%乙醇溶液定容至3mL;分别在上述7支具塞试管中精密加入0.4mL的5%亚硝酸钠溶液,摇匀后静置6分钟;加入0.4mL的10%Al(NO3)3溶液,摇匀后静置6分钟;加入4mL的5%NaOH溶液,定容至10mL后静置15分钟,于紫外波长为510nm处测定其分光光度值,重复三次平行试验。以芦丁浓度为标准曲线的横坐标,分光光度值为标准曲线的纵坐标,作回归曲线。
根据上述方法,分别测定上述化香树叶粉末(Ah)、市售化香虫茶(Af)、实施例1制备得到的化香虫茶(At)样品待测液的总黄酮含量,重复三次平行试验,计算这三种样品待测液的总黄酮提取率。
结果如表3所示:
表3:黄酮提取率
结果表明,实施例1制备得到的化香虫茶水提取液与化香树叶水提取液和市售化香虫茶的总黄酮含量及总黄酮提取率均无明显差异。采用黄粉虫生产化香虫茶(At)的总黄酮含量与市售化香虫茶(Af)仅相差0.18mg。
(3)清除羟基自由基能力研究
准备3支10mL具塞试管,分别标记为A1(损伤)、Axo(未加药)、Ax(加药),将上述3支试管中分别加入0.80mL的硫酸亚铁溶液(浓度为9mmol/mL);在Axo、Ax试管分别加1mL化香虫茶水提取液,A1则加入1mL的蒸馏水;在A1、Ax试管加入1mL 1%的H2O2溶液,Axo则加入1mL蒸馏水;混匀后置于恒温水浴锅进行37℃保温半个小时;在3支试管中加入0.60mL水杨酸-乙醇溶液(水杨酸溶液浓度为9mmol/mL)后定容至10mL,混匀,在紫外波长为520nm处测定分光光度值。计算羟基自由基清除率,以待测液的浓度为横坐标,羟基自由基的清除率为纵坐标,制作回归曲线,计算该待测液的IC50,以芦丁的IC50为对照,以评估虫茶水提液的羟基自由基清除能力。
结果如表4-5和图1-3所示。
表4:各样品对羟基自由基的清除率
表5:各样品清除羟基自由基的回归方程
以上结果表明,化香虫茶水提取液与芦丁溶液的IC50相差1.26mg/mL,故在体外清除羟基自由基方面,化香虫茶水提取液清除羟基自由基的能力较好,并且其清除羟基自由基的能力呈现一定的浓度效应。
(4)清除DPPH自由基能力研究
准备3支具塞试管,分别标记为A0、A、B号试管,在A0号试管中加入1.90mL的DPPH-50%乙醇溶液(DPPH溶液浓度为0.04mg/mL)和0.10mL的50%乙醇溶液;A号试管加入1.90mL的DPPH-50%乙醇溶液和0.10mL化香虫茶水提取液;B号试管中加入1.90mL的50%乙醇溶液和0.10mL化香虫茶水提取液;将上述3支试管混匀后,加盖并在室温下黑暗反应30分钟;随后在紫外波长为525nm处测定其分光光度值。计算DPPH自由基清除率,以待测液的浓度为横坐标,DPPH自由基的清除率为纵坐标,制作回归曲线,计算该待测液的IC50,以芦丁的IC50为对照,以评估虫茶水提液对DPPH自由基的清除能力。
结果如表6-7和图4-6所示。
表6:各样品对DPPH自由基的清除率
表7:各样品清除DPPH自由基的回归方程
结果表明,化香虫茶水提取液与市售化香虫茶水提取液抗自由基能力无显著差异,其中IC50相差为0.24mg/mL。上述四种样品清除体外DPPH自由基均呈一定的浓度效应,且化香虫茶水提取液与芦丁溶液的体外清除DPPH自由基能力无显著差异,说明化香虫茶水提取液有较好的抗DPPH自由基能力。
(5)铁还原能力研究
准备一支10mL具塞试管(A1)中依次加入1.00mL化香虫茶水提取液、2.50mL的PBS溶液(pH 6.6)、2.50mL质量分数为1%的铁氰化钾溶液,混匀后置于恒温水浴锅中50℃保温20分钟;将其冷却至室温,加入2.5mL质量分数为10%的三氯乙酸,即得含有化香虫茶的混合液;在上述试管中取2.50mL含有化香虫茶的混合液于新的试管中,并依次加入2.50mL的蒸馏水、2.50mL的1%三氯化铁溶液;A0管同A1管的方法,将1.00mL化香虫茶水提取液换成蒸馏水;将上述试管混匀后静置10分钟,于紫外波长为780nm处测定分光光度值。铁还原能力以ΔA=A1-A0表示,以待测液的浓度为横坐标,铁还原能力为纵坐标,制作回归曲线,计算该待测液的IC50,以芦丁的IC50为对照,以评这三种水提液的铁还原能力。结果如表8和图7-9所示。
表8:各样品的铁还原能力
由结果可知,化香虫茶水提液与市售化香虫茶、化香树叶还原二价铁的能力无显著差异,且这三种样品与芦丁溶液还原二价铁能力无显著差异。总之,这四种样品均表现良好的铁还原能力。
(6)清除氧自由基能力研究
第一次测定(A1),准备一个玻璃比色杯,分别依次加入2.00mL的Tris-HCl缓冲液(pH为8.2,浓度为50mmol/L)、0.20mL的灿烂绿溶液(浓度为2×10-4mol/L),0.70mL的化香虫茶水提取液、0.10mL邻苯三酚溶液(浓度为50mmol/mL),立即摇匀并静置2秒后测定紫外波长为630nm的吸光光度值,每隔30秒记录吸光光度值,持续到4分钟。第二次测定(A2),方法同第一次测定,将0.70mL的化香虫茶水提取液换成蒸馏水,测定其分光光度值。计算氧自由基的清除率,以待测液的浓度为横坐标,氧自由基的清除率为纵坐标,制作回归曲线,计算该待测液的IC50(mg/mL),以芦丁的IC50为对照,以评估虫茶及原植物水提液的氧自由基清除能力。
结果如表9-10和图10-11所示。
表9:各样品对氧自由基的清除率
表10:各样品对氧自由基清除率的回归方程
结果表明,化香虫茶水提液与市售化香虫茶、化香树叶氧自由基清除能力无显著差异,且这三种样品与芦丁溶液氧自由基清除能力无显著差异。所以化香虫茶的水提取液具有良好的体外清除氧自由基能力。
实施例3:基于GC-MS对化香虫茶的定性、定量研究
实施例1制备得到的化香虫茶(At)、化香树叶(Ah)和市售化香虫茶(Af)的化学成份由上海鹿明生物科技有限公司代理完成。具体操作为:
分别将实施例1制备得到的化香虫茶(At)、化香树叶(Ah)和市售化香虫茶(Af)随机分成6份,共18个样本。
分别精密称取上述所获18个样本的60mg样品,将其放入30支1.50mL的离心管中,进一步分别加入40μL内标(由甲醇配置0.30mg/mL的L-2-氯-苯丙氨酸);在上述离心管中分别依次加入两颗小钢珠、360μL已预冷的甲醇,将其置于-20℃冰箱中5分钟;取出后放入研磨机中进行60Hz研磨2分钟;将其放入冰水浴中进行超声波提取30分钟;取出将其分别加入200μL氯仿溶液、400μL蒸馏水,置于涡旋仪中涡旋2分钟;再将其进行超声波提取30分钟;取出后放置冰箱-20℃静置30分钟;取出后将其进行4℃条件下13000×g离心10分钟,分别取200μL的上清液装入玻璃衍生瓶中;从上述提取所有样本的上清液中吸取等体积的量,混合后再将其分别吸取200μL于6份玻璃衍生瓶中作为质控样本(QC);将上述获得的36个上清液样品进行离心浓缩后放入干燥器进行挥干;接着向挥干后的玻璃衍生小瓶中加入80μL的甲氧胺盐酸盐吡啶溶液(15mg/mL),涡旋震荡2分钟后,将其置于震荡培养箱中进行37℃、90分钟的肟化反应;将样本取出后加入80μL的BSTFA(含1%TMCS)衍生试剂和20μL的正己烷,再分别加入10μL的11种内标(由氯仿配置0.16mg/mL的辛酸甲酯(C8:0)、壬酸甲酯(C9:0)、癸酸甲酯(C10:0)、十二烷酸甲酯/月桂酸甲酯(C12:0)、十四烷酸甲酯/肉豆蔻酸甲酯(C14:0)、十六烷酸甲酯/棕榈酸甲酯(C16:0)和0.08mg/mL的八烷酸甲酯/硬脂酸甲酯(C18:0)、二十烷酸甲酯/花生酸甲酯(C20:0)、二十二烷酸甲酯/山俞酸甲酯(C22:0)、二十四烷酸甲酯/木蜡酸甲酯(C24:0)、二十六烷酸甲酯(C26:0)),涡旋震荡2分钟后,将其置于70℃反应60分钟;反应完取出样本并在室温放置30分钟,备用以进行GC-MS检测。
气相色谱条件:实验使用HP-5MS毛细管柱(30m×0.25mm×0.25μm,Agilent J&WScientific,Folsom,CA,USA),载气为高纯氦气(纯度不小于99.999%),流速为1.0mL/min,进样口的温度为260℃。进样量为1μL,以4:1分流进样,溶剂延迟5分钟。程序升温:柱温箱的初始温度为60℃,保持0.5分钟;起始以8℃/min的速度使程序升温至125℃;以4℃/min的速度使程序升温至210℃;以5℃/min的速度使程序升温至270℃;以10℃/min的速度使程序升温至305℃,保持3分钟。
质谱条件:电子轰击离子源(EI)的温度为230℃,四级杆的温度为150℃,电子能量70eV。扫描方式为全扫描模式(SCAN),质量扫描范围m/z:50-500。
数据的处理和分子鉴定:采用基于独立数据采集(DIA)模式小分子质量反卷积(MS-DIAL)的方法结合上海鹿明生物科技有限公司自研的LUG数据库(Untarget databaseof GC-MS from Lumingbio)、NIST数据库对原始数据进行定性和定量分析。将GC-MS的原始数据(D格式)经AnalysisBaseFileConverter软件转换为分析基本文件abf格式以便快速检索数据;之后导入MS-DIAL软件进行预处理,通过分析两个连续的数据轴,有效地发现前体离子峰;使用MS2Dec算法提取色谱中的“模型峰”,去除背景噪声,通过保留时间、精确分子质量,与公共数据库匹配相似度实现化合物的定性。
结果表明,在比较化香树叶的基础上,化香树叶黄粉虫虫茶的显著上调成份比市售化香虫茶的显著上调成份多,其中N-乙酰氨基半乳糖、泛酸、豆固醇、L-亮氨酸、L-色氨酸、烟酰胺、5,7-二羟基-4'-甲氧基异黄酮和磷乙酸酯为共有成份;说明通过黄粉虫生产的化香虫茶比市售化香虫茶的显著上调成份更多,且含有上述8种共有的上调成份。
实施例4:基于LC-MS对化香虫茶的定性、定量研究
(1)检测样本的准备和预处理
分别精密称取实施例1制备得到的化香虫茶(At)、化香树叶(Ah)和市售化香虫茶(Af)各80mg,共30个样本,每个样品10个平行。将上述样品分别放入1.50mL的离心管中,加入20μL内标(由甲醇配置0.30mg/mL的L-2-氯-苯丙氨酸),1mL的甲醇-水(V:V=7:3);在离心管中加入两个小钢珠,-20℃放置2分钟预冷后加入研磨机进行2分钟60Hz研磨;将其取出放入冰水浴进行超声波提取30分钟,-20℃过夜静置;再进行离心10分钟(13000×g,4℃),用注射器吸取上述样品150μL的上清液,其中质控样本(QC)由所有样本的上清液等体积混合制备而成;使用0.22μm的有机相针孔过滤器过滤后,转移到LC进样小瓶,-80℃下保存,备用以进行LC-MS检测。
(2)液相色谱的条件
采用AB ExionLC超高效液相串联QE高分辨质谱仪组成的液质联用系统,色谱柱:ACQUITY UPLC HSS T3(100mm×2.1mm,1.8um);柱温:45℃;流动相:A-水(含0.1%甲酸),B-乙腈(含0.1%甲酸);流速:0.35mL/min;进样体积:2μL;程序的梯度洗脱见表11。
表11:程序的梯度洗脱信息
(3)质谱的条件
离子源:ESI;样品质谱信号采集分别采用正负离子扫描模式;质谱参数如表12。
表12:质谱的参数
(4)数据的处理和分子鉴定
通过Progenesis QI v2.3软件(Nonlinear Dynamics,Newcastle,UK)对原始数据进行基线过滤、峰识别、积分、保留时间校正、峰对齐和归一化;使用The Human MetabolomeDatabase(HMDB)、Lipidmaps(v2.3)和METLIN数据库基于精确质量数、二级碎片以及同位素分布进行鉴定样本的相关化学成份。将Ah样品定义为H组、Af样品为F组、At样品为T1组。
(5)检测结果
结果分别如图12和13所示。通过比较实施例1制备得到的化香虫茶(At)和市售化香虫茶(Af)的成份,发现实施例1制备得到的化香虫茶(At)的显著成份比市售化香虫茶(Af)多,其中,二者共含有85种共有的显著成份;化香虫茶(At)的显著成份比市售化香虫茶(Af)多1005种,其中983种显著成份是化香虫茶(At)比市售化香虫茶(Af)多的特异成份;说明化香虫茶(At)与市售化香虫茶(Af)含有三分之二的共有成份,并且前者的显著差异成份数量更多;将化香虫茶(At)与化香树叶(Ah)比较,两者显著下调成份的数量接近,且含有811(66.1%)种相同的显著下调成份。
结果表明,化香虫茶(At)的显著差异标志成份主要为三萜、类黄酮、黄酮苷、黄烷、氨基酸或肽和类似物、甘油磷酸酯、醌和氢醌类脂、类异戊二烯、萜烯糖苷、孕激素类固醇、甾醇、类固醇和类二十烷酸等,说明黄粉虫可能对这些成份有较好的富集作用,并聚集于虫沙被排出体外。
实施例5:化香虫茶的网络药理学研究
(1)虫茶的活性成份筛选
得到实施例1制备得到的化香虫茶(At)的化学成份后,将每个成份通过用PubChem数据库进行检索并获得相应的三维结构、SMILSS和CAS号。进一步使用DruLiTo软件对这些成份进行类药性分析,将符合类药性规则的成份经过SWISS数据库预测与ADME相关的信息,以初步筛选出可被人体肠道吸收的成份。将这些成份定义为活性成份,并建立化香树叶黄粉虫虫茶的活性成份数据集。
(2)活性成份扰动细胞所致的转录分析
将化香虫茶(At)的活性成份和CMap数据库的build02数据集进行映射,以获取相关成份作为扰动因子所致的芯片原始数据(CEL文件)。对每个扰动因子相应的原始数据分别进行预处理,由affyPLM包实现芯片原始数据的质量控制,以剔除不合格的芯片数据。通过affy包对质量合格的芯片数据进行背景校正、标准化和汇总,以消除不同样品测量之间的非实验差异,并获得基因表达矩阵。将这些表达矩阵分别进行分组,由limma包分析并获得1倍差异表达的显著基因。
(3)活性成份的药效团靶点预测
将本实施例步骤(1)的活性成份与LC-MS所测T1组比H组的显著上调成分进行映射,结合本实施例步骤(2)的转录分析结果,即为化香虫茶(At)主要活性成份数据集。将每个主要活性成份的三维结构提交PharmMapper服务器进行药效团靶点的预测。根据服务器反馈的结果,选取校正后打分≥0.5的靶点通过UniProt数据库(https://www.uniprot.org/uniprot/)筛选出人源靶点并注释为官方名称(official symbol),即得到本发明深入分析的640个药效团靶点。
(4)上游转录因子及激酶的富集
由于基因表达谱分析获得全基因组范围内所检测的mRNA水平与蛋白质水平呈弱相关性,可通过X2K服务器计算相关基因结合位点的过表达,以确定转录因子与差异表达基因的联系。将上述所获1倍差异表达的基因提交于该服务器,以计算其上游转录因子和相关激酶。以P≤0.05为阈值,获得的上游转录因子及相关激酶为显著的功能蛋白。
(5)蛋白互作网络模型(PPI)的构建
综合本实施例步骤(4)获得的上游转录因子、激酶与步骤(3)获得的药效团靶点,将其通过STRING数据库进行分析蛋白的相互作用关系,并将物种的设置为Homo sapiens,置信度分值≥0.9。将服务器反馈的结果文件导入Cytoscape3.6.1软件进行可视化,使用该软件的NetworkAnalyzer插件进行分析,并构建蛋白互作网络模型。
(6)成份-靶点互作网络模型的构建
通过活性成份与药效团靶点的作用关系,将药效团靶点与上述所获的1倍差异表达的基因蛋白、上游转录因子及相关激酶进行映射,以构建成份-靶点互作的网络模型。将活性成份与具有药效团效应的1倍差异基因蛋白、上游激酶、转录因子作为输入文件,通过Cytoscape3.6.1软件进行构建活性成份-药效团靶点的互作网络模型。由NetworkAnalyzer插件分析整个网络模型的拓扑结构,根据度值、接近中心性等拓扑参数获得网络的关键节点,以揭示调控整个网络的重要成份和蛋白。
(7)活性成份与关键靶点的分子对接
根据本实施例步骤(6)构建的活性成份-药效团靶点的互作网络模型,以整个网络模型中接近中心性≥0.4的活性成份、药效团靶点作为分子对接的研究对象。将本实施例步骤(1)获得的三维结构作为配体,药效团靶点蛋白的三维结构为受体,进行分子对接任务。在PDB数据库检索信息较全面的蛋白晶体结构,以人类物种、包含原配体分子和分辨率≤0.35nm为优先条件进行筛选,并下载蛋白晶体的立体结构。利用LEDOCK程序对虫茶活性成份与药效团靶点蛋白进行半柔性分子对接,即对接程序设置受体蛋白为刚性分子,配体为柔性分子,采用模拟退火和遗传算法交叉运算,进一步搜索能量最低的构象。以蛋白晶体中的天然配体为对照,对接后天然配体的RMSD值应小于用以验证对接程序中参数设置的准确性,并进一步分析该蛋白与虫茶活性成份的相互作用。程序运行前需要对蛋白晶体进行去除水分子、杂质并添加氢键等预处理,同时将配体分子去除极性氢、添加电荷等处理后实施MM2力场优化。将蛋白晶体中的天然配体分子为中心扩大或者查询相关文献以确定该蛋白的活性位点作为对接盒子。对接结果由配体在受体活性空腔下不同能量空间构象的Score分值大小进行排序展示。
(8)GO富集分析
GO富集(Gene Ontology)可以分析靶点的分子功能、生物过程及细胞成份,分析过程由基因富集分析包(clusterProfiler)实现,将药效团靶点、1倍差异表达基因一起富集分析。
(9)KEGG富集分析
KEGG通路(Kyoto encyclopedia of genes and genomes)可分析靶点在细胞内的生化过程,分析过程由人类全基因组注释包(org.Hs.eg.db)和基因富集分析包(clusterProfiler)实现,将药效团靶点、1倍差异表达基因一起富集分析。
(10)疾病的富集分析
为探讨虫茶活性成份潜在治疗的相关疾病,将上述所获的所有基因进行DO(Disease Ontology)富集分析,由DOSE包的超几何模型方法实现基因集与疾病的关联分析。将富集结果与药效团靶点、成份进行构建相互作用网络模型,以进行深入研究。
(11)虫茶的网络药理结果
结果表明,由相关激酶或转录因子所富集的显著疾病共有185条,其中134条为癌症相关疾病,9条为炎症、免疫相关疾病,12条为血管、白血病相关疾病,2条为肥胖相关疾病,4条为肌肉相关疾病,3条为骨质相关疾病等。根据网络拓扑结构可知,Degree值≥3、接近中心性≥0.3的成份为皮质酮、花生酸、黄酮酸酯、赖诺普利、卡诺霉素U I49、FuromammeaG、育亨宾碱、乙罂粟碱、海罂粟胺、布地缩松、Brosimacutin D、Ginsenoyne H、PGF1a乙醇、KH 1049等,说明这些活性成份对相关疾病的防治具有较高的贡献,而TP53、CCND1、AR、CDKN1B、E2F1、ESR1、PCNA、CAMK4、CAMK2A、MAPK9、FLI1、TGM2、FOXM1、CDK2、CDK6、WEE1、UBTF、CDK7、USF1、EPHA8和ZBTB7A等21种中枢蛋白为上述PPI、CPI网络所证明的重要调控蛋白,其富集于显著通路的比例为89.37%,说明这21种中枢蛋白在细胞内调控相关蛋白并防治相关疾病具有参考的价值,后续研究可关注这些成份、中枢蛋白的分子作用及调控功能。综上所述,化香虫茶的主要活性成份具有多靶点的作用,其在细胞内主要调控上述21种中枢蛋白,以进一步影响相关协作蛋白的功能。进一步证明化香虫茶的主要活性成份在癌症、炎症、病毒感染、高脂肪和血管疾病等方面有一定的防治潜力。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种化香虫茶的生产方法,其特征在于,利用黄粉虫幼虫处理化香树叶得到化香虫茶。
2.根据权利要求1所述的生产方法,其特征在于,以化香树叶饲养黄粉虫幼虫,将黄粉虫幼虫生产的虫沙烘干,即得化香虫茶。
3.根据权利要求2所述的生产方法,其特征在于,所述的黄粉虫幼虫为60~90日龄的黄粉虫幼虫。
4.根据权利要求2所述的生产方法,其特征在于,所述的化香树叶为经烘干后的化香树叶嫩叶。
5.根据权利要求2所述的生产方法,其特征在于,所述的黄粉虫幼虫密度为0.088~0.269g/cm2。
6.根据权利要求2所述的生产方法,其特征在于,
所述的烘干前还包括过筛的操作;
所述的烘干为恒温烘干;进一步为50~70℃恒温烘干2~4h。
7.根据权利要求2所述的生产方法,其特征在于,所述的饲养的条件为通风干燥、卫生的环境中。
8.一种化香虫茶,其特征在于,通过权利要求1~7任一所述的生产方法制备得到。
9.权利要求8所述的化香虫茶在制备治疗和/或预防由相关激酶或转录因子作用引起的疾病的药物中的应用。
10.根据权利要求9所述的应用,其特征在于,所述的由相关激酶或转录因子作用引起的疾病包括癌症、炎症、免疫相关疾病、血管、白血病相关疾病、肥胖相关疾病、肌肉相关疾病和骨质相关疾病中的至少一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110503612.2A CN113208013A (zh) | 2021-05-10 | 2021-05-10 | 一种化香虫茶及其生产方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110503612.2A CN113208013A (zh) | 2021-05-10 | 2021-05-10 | 一种化香虫茶及其生产方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113208013A true CN113208013A (zh) | 2021-08-06 |
Family
ID=77093958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110503612.2A Pending CN113208013A (zh) | 2021-05-10 | 2021-05-10 | 一种化香虫茶及其生产方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113208013A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107980985A (zh) * | 2017-12-01 | 2018-05-04 | 赤水市桫龙虫茶饮品有限责任公司 | 一种虫茶制备工艺 |
CN109907143A (zh) * | 2019-02-01 | 2019-06-21 | 广州柏芳生物科技有限公司 | 一种利用食用昆虫快速制作新型虫茶的方法 |
CN110074226A (zh) * | 2019-05-23 | 2019-08-02 | 广西壮族自治区药用植物园 | 提高野生虫茶纯度的生产方法 |
CN112616968A (zh) * | 2020-11-24 | 2021-04-09 | 赤水山宝生态茶业开发有限公司 | 一种虫茶生产工艺及卫生处理装置 |
-
2021
- 2021-05-10 CN CN202110503612.2A patent/CN113208013A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107980985A (zh) * | 2017-12-01 | 2018-05-04 | 赤水市桫龙虫茶饮品有限责任公司 | 一种虫茶制备工艺 |
CN109907143A (zh) * | 2019-02-01 | 2019-06-21 | 广州柏芳生物科技有限公司 | 一种利用食用昆虫快速制作新型虫茶的方法 |
CN110074226A (zh) * | 2019-05-23 | 2019-08-02 | 广西壮族自治区药用植物园 | 提高野生虫茶纯度的生产方法 |
CN112616968A (zh) * | 2020-11-24 | 2021-04-09 | 赤水山宝生态茶业开发有限公司 | 一种虫茶生产工艺及卫生处理装置 |
Non-Patent Citations (2)
Title |
---|
王睿等: "化香虫茶总黄酮对CCl_4诱导小鼠肝损伤的预防效果", 《食品工业科技》 * |
许利嘉等: "茶文化中的奇葩――虫茶", 《中国现代中药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102512458A (zh) | 蛹虫草活性组分的半仿生提取方法 | |
Yuan et al. | Comparative nutritional characteristics of the three major Chinese Dendrobium species with different growth years | |
CN115136959B (zh) | 一种豆大蓟马取食抑制剂及其筛选方法与应用 | |
Chang et al. | In vitro propagation of bulblets and LC–MS/MS analysis of isosteroidal alkaloids in tissue culture derived materials of Chinese medicinal herb Fritillaria cirrhosa D. Don | |
Wang et al. | Effects of storage on brown rice (Oryza sativa L.) metabolites, analyzed using gas chromatography and mass spectrometry | |
Zhang et al. | Characterization of bioactives and in vitro biological activity from Protaetia brevitarsis larval extracts obtained by different pretreatment extractions | |
CN113599467A (zh) | 一种藏红曲、藏药红曲提取物、制备方法及应用 | |
Imelda et al. | Hippobroma longiflora L Leaves as a natural inhibitor of cataract progression: A comprehensive study integrating ethanol extract, HPLC, and molecular docking approaches | |
Ali Ahmed et al. | In vitro production of gymnemic acid from Gymnema sylvestre (Retz) R. Br. ex Roemer and Schultes through callus culture under abiotic stress conditions | |
CN113208013A (zh) | 一种化香虫茶及其生产方法与应用 | |
CN114470150B (zh) | 一种鸡源性小分子肽在制备预防和改善肝损伤及其继发症状产品中的应用及该产品 | |
Qi et al. | Metabolomics and network pharmacology profiling revealed soilless cultivation reduces the accumulation of harmful compounds in Houttuynia cordata | |
CN116327806A (zh) | 一种蝉蜕加工方法及其蝉蜕质量检测方法 | |
Syamsudin | Standardization of extract of Leucaena leucocephala (lmk) De Wit seeds by?-glucosidase inhibitor | |
CN102046025A (zh) | 含有苯并噁嗪类的谷物制品的用于增进健康目的的用途 | |
Feng et al. | Plant volatile organic compounds attractive to Lygus pratensis | |
CN105613285A (zh) | 一种快速提高丹参中迷迭香酸含量的方法 | |
CN114342882A (zh) | 一种提高地鳖内在品质的方法 | |
Keerthana et al. | Antidiabetic activity of chemical constituents in Elaeocarpus tectorius fruits-an in silico study | |
Lian et al. | Association of wheat chaff derived silica fiber and esophageal cancer in north China | |
CN111317741A (zh) | 用于治疗鼻咽癌的中药口服制剂及其鉴别方法与应用 | |
Zhang et al. | Botanical characterization, phytochemistry, biosynthesis, pharmacology clinical application, and breeding techniques of the Chinese herbal medicine Fritillaria unibracteata | |
CN1680584A (zh) | 提高标准化的松果菊制备物的免疫调节活性的方法 | |
CN106172409B (zh) | 一种香蕉处理剂及其使用方法 | |
Jin et al. | Exploration of phytochemicals and biological functions of Kadsura coccinea pericarpium based on LC-MS and network pharmacology analysis and experimental validation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210806 |
|
RJ01 | Rejection of invention patent application after publication |